New SVP at Obagi Medical Products

Obagi Medical Products, Inc. (OMPI) appointed Mark T. Taylor as senior vice president, corporate development and investor relations.

He comes to Obagi with more than 20 years of experience working with specialty pharmaceutical companies in high-level capacities.

Most recently, Taylor was at Roth Capital Partners, LLC where for over a six-year tenure he served health care clients in institutional sales, investment banking, and equity research. From May of 2003 to October of 2007, he was Roth’s specialty pharmaceutical analyst where he published on as many as 25 companies, including Obagi.

Albert F. Hummel, president and chief executive officer, commented, “We are extremely pleased to welcome Mark to our team. He brings valuable experience, insights, and a particular skill base that can readily assist us in our mission to build a much larger and more valuable company. In this new role, Mark will work with the team to build the base business internationally as well as to identify new sources of revenue from licensing, acquisition, and strategic partnerships. Additionally, because of his unique experience with institutional investors, Mark will assist me and Preston Romm in Investor Relations.”